Product Description: Elafibranor (GFT505) is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively. Elafibranor can be used for the study of primary biliary cholangitis[1].
Applications: Metabolism-sugar/lipid metabolism
Formula: C22H24O4S
References: [1]Liu ZM, et al. Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.Expert Opin Investig Drugs. 2015 May;24(5):611-21./[2]Ratziu V, et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016 May;150(5):1147-1159./[3]Hanf R, et al. The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.Diab Vasc Dis Res. 2014 No
CAS Number: 923978-27-2
Molecular Weight: 384.49
Compound Purity: 99.13
Research Area: Metabolic Disease; Inflammation/Immunology
Solubility: DMSO : ≥ 33 mg/mL
Target: PPAR
Deutsch
English
